The Prognostic Impact of Synchronous Ipsilateral Multiple Breast Cancer: Survival Outcomes according to the Eighth American Joint Committee on Cancer Staging and Molecular Subtype
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: In the current American Joint Committee on Cancer staging system of breast cancer, only tumor size determines T-category regardless of whether the tumor is single or multiple. This study evaluated if tumor multiplicity has prognostic value and can be used to subclassify breast cancer. Methods: We included 5,758 patients with invasive breast cancer who underwent surgery at Samsung Medical Center, Seoul, Korea, from 1995 to 2012. Results: Patients were divided into two groups according to multiplicity (single, n = 4,744; multiple, n = 1,014). Statistically significant differences in lymph node involvement and lymphatic invasion were found between the two groups (p < .001). Patients with multiple masses tended to have luminal A molecular subtype (p < .001). On Kaplan-Meier survival analysis, patients with multiple masses had significantly poorer disease-free survival (DFS) (p = .016). The prognostic significance of multiplicity was seen in patients with anatomic staging group I and prognostic staging group IA (p = .019 and p = .032, respectively). When targeting patients with T1-2 N0 M0, hormone receptor–positive, and human epidermal growth factor receptor 2 (HER2)–negative cancer, Kaplan-Meier survival analysis also revealed significantly reduced DFS with multiple cancer (p = .031). The multivariate analysis indicated that multiplicity was independently correlated with worse DFS (hazard ratio, 1.23; 95% confidence interval, 1.03 to 1.47; p = .025). The results of this study indicate that tumor multiplicity is frequently found in luminal A subtype, is associated with frequent lymph node metastasis, and is correlated with worse DFS. Conclusions: Tumor multiplicity has prognostic value and could be used to subclassify invasive breast cancer at early stages. Adjuvant chemotherapy would be necessary for multiple masses of T1–2 N0 M0, hormone-receptor-positive, and HER2-negative cancer.
Abstract
Background: In the current American Joint Committee on Cancer staging system of breast cancer, only tumor size determines T-category regardless of whether the tumor is single or multiple. This study evaluated if tumor multiplicity has prognostic value and can be used to subclassify breast cancer. Methods: We included 5,758 patients with invasive breast cancer who underwent surgery at Samsung Medical Center, Seoul, Korea, from 1995 to 2012. Results: Patients were divided into two groups according to multiplicity (single, n = 4,744; multiple, n = 1,014). Statistically significant differences in lymph node involvement and lymphatic invasion were found between the two groups (p < .001). Patients with multiple masses tended to have luminal A molecular subtype (p < .001). On Kaplan-Meier survival analysis, patients with multiple masses had significantly poorer disease-free survival (DFS) (p = .016). The prognostic significance of multiplicity was seen in patients with anatomic staging group I and prognostic staging group IA (p = .019 and p = .032, respectively). When targeting patients with T1-2 N0 M0, hormone receptor–positive, and human epidermal growth factor receptor 2 (HER2)–negative cancer, Kaplan-Meier survival analysis also revealed significantly reduced DFS with multiple cancer (p = .031). The multivariate analysis indicated that multiplicity was independently correlated with worse DFS (hazard ratio, 1.23; 95% confidence interval, 1.03 to 1.47; p = .025). The results of this study indicate that tumor multiplicity is frequently found in luminal A subtype, is associated with frequent lymph node metastasis, and is correlated with worse DFS. Conclusions: Tumor multiplicity has prognostic value and could be used to subclassify invasive breast cancer at early stages. Adjuvant chemotherapy would be necessary for multiple masses of T1–2 N0 M0, hormone-receptor-positive, and HER2-negative cancer.
참고문헌 (28)
- Qualheim RE, "Breast carcinoma with multiple sites of origin", Cancer, 10, pp.460~468 (1957)
- Bendifallah S, "Multiple synchronous (multifocal and multicentric) breast cancer: clinical implications", Surg Oncol, 19, pp.e115~e123 (2010)
- Yerushalmi R, "Does multicentric", multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence, 2009, pp.117, 365~370
- Egan RL, "Multicentric breast carcinomas: clinical-radiographicpathologic whole organ studies and 10-year survival", Cancer, 49, pp.1123~1130 (1982)
- Tot T, "Axillary lymph node status in unifocal, multifocal, and diffuse breast carcinomas: differences are related to macrometastatic disease", Ann Surg Oncol, 19, pp.3395~3401 (2012)
- Duraker N, "Axillary lymph node status and prognosis in multifocal and multicentric breast carcinoma", Breast J, 20, pp.61~68 (2014)
- Cabioglu N, "Increased lymph node positivity in multifocal and multicentric breast cancer", J Am Coll Surg, 208, pp.67~74 (2009)
- Andea AA, "Correlation of tumor volume and surface area with lymph node status in patients with multifocal", multicentric breast carcinoma, 2004, pp.100, 20~27
- Joergensen LE, "Multifocality as a prognostic factor in breast cancer patients registered in Danish Breast Cancer Cooperative Group (DBCG) 1996-2001", Breast, 17, pp.587~591 (2008)
- Coombs NJ, "Multifocal and multicentric breast cancer: does each focus matter?", J Clin Oncol, 23, pp.7497~7502 (2005)
- Vlastos G, "Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer", Ann Surg Oncol, 7, pp.581~587 (2000)
- Rezo A, "Tumor size and survival in multicentric and multifocal breast cancer", Breast, 20, pp.259~263 (2011)
- Lynch SP, "Multifocality and multicentricity in breast cancer and survival outcomes", Ann Oncol, 23, pp.3063~3069 (2012)
- Pedersen L, "The prognostic influence of multifocality in breast cancer patients", Breast, 13, pp.188~193 (2004)
- Tot T, "Breast cancer multifocality, disease extent, and survival", Hum Pathol, 42, pp.1761~1769 (2011)
- Giuliano AE, "Eighth edition of the AJCC cancer staging manual: breast cancer", Ann Surg Oncol, 25, pp.1783~1785 (2018)
- Hammond ME, "American Society of Clinical Oncology", College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, 2010, pp.28, 2784~2795
- Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2014, pp.138, 241~256
- Goldhirsch A, "Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Ann Oncol, 22, pp.1736~1747 (2011)
- Litton JK, "Multifocal breast cancer in women < or =35 years old", Cancer, 110, pp.1445~1450 (2007)
- Boyages J, "Multifocal breast cancer and survival: each focus does matter particularly for larger tumours", Eur J Cancer, 46, pp.1990~1996 (2010)
- Neri A, "Clinical significance of multifocal and multicentric breast cancers and choice of surgical treatment: a retrospective study on a series of 1158 cases", BMC Surg, 15, pp.1~ (2015)
- O’Daly BJ, "The accuracy of combined versus largest diameter in staging multifocal breast cancer", J Am Coll Surg, 204, pp.282~285 (2007)
- Weissenbacher TM, "Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?", Breast Cancer Res Treat, 122, pp.27~34 (2010)
- Ustaalioglu BO, "The importance of multifocal", multicentric tumor on the disease-free survival of breast cancer patients: single center experience, 2012, pp.35, 580~586
- Fish EB, "Assessment of tumor size for multifocal primary breast cancer", Ann Surg Oncol, 5, pp.442~446 (1998)
- Moon HG, "Effect of multiple invasive foci on breast cancer outcomes according to the molecular subtypes: a report from the Korean Breast Cancer Society", Ann Oncol, 24, pp.2298~2304 (2013)
- Sparano JA, "Prospective validation of a 21-gene expression assay in breast cancer", N Engl J Med, 373, pp.2005~2014 (2015)